iBio, Inc. 8K

iBio, Inc. announced its FY 2026 results and a corporate update, emphasizing its move into clinical stage development, significant financings, leadership changes, and a strengthened balance sheet despite higher R&D-driven losses and an intangible asset impairment.

On August 28, 2026, iBio, Inc. reported its financial results for the fiscal year ended June 30, 2026 and provided a corporate update highlighting its transition to a clinical-stage biotechnology company, including advancement of obesity and cardiometabolic programs IBIO-600 into a Phase 1 trial and IBIO-610 and IBIO-800 into IND‑enabling development, the in‑licensing of AstralBio’s amylin receptor antibody program, completion of a public offering with total potential gross proceeds of up to $100 million in August 2025 and a $26 million private placement in January 2026, entry into an at‑the‑market sales agreement with Jefferies LLC for up to $100 million of common stock, board and management enhancements, and disclosure of a $33.0 million net loss on $0.1 million in revenue, increased R&D spending, a $5.0 million impairment of an indefinite‑lived intangible asset, and cash, cash equivalents and debt securities of approximately $88.0 million as of June 30, 2026.

Filing Facts

CIK

1420720

Ticker

-

Form

8K

Source Type

sec

Accession

0001420720-26-000019

Alert Tier

6